Tech Company Financing Transactions

ImmPACT Bio USA Funding Round

Decheng Capital, Foresite Capital and venBio invested in a $111 million Series B funding round for ImmPACT Bio USA. The funding round closed on 1/28/2022.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4010 Adolfo Rd.
Camarillo, CA 93012
USA

Phone

Undisclosed

Website

Email Address

Not Recorded

Overview

ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rick Kendall

        

VP - R & D

Frank Calzone

        

Browse more venture capital transactions:

Prev: 1/28/2022: Autograph.io venture capital transaction
Next: 1/28/2022: Ambient.ai venture capital transaction

Share this article

News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary